You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis While carbapenems are among the most prescribed antibiotics for infections caused by these organisms carbapenem resistance conferred by zinc based metallo carbapenemases Amber Class B is a growing global health concern that threatens to erode the efficacy of these antibiotics both in th ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis This crisis has been further amplified by the recent emergence of the NDM andquot super bug geneandquot a zinc based metallo lactamase Amber Class B in Enterobacteriaceae Members of this family of resistance enzymes are found on promiscuous plasmids with other MDR resistance mechanisms ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Urine Test for the Early Detection of Liver Cancer

    SBC: JBS SCIENCE INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of a urine test for the early detection of liver cancer The need to develop an effective method of detecting hepatocellular carcinoma HCC is urgent HCC is the third leading cause of cancer deaths and has a year survival rate of less than If HCC is identified early the survival rate can be as high as The survival rate drops significantly however to as l ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. In-Patient Pediatric Gastrojejunal Tube Cleaner Eliminating Surgical Intervention

    SBC: ACTUATED MEDICAL, INC.            Topic: NICHD

    DESCRIPTION provided by applicant In this Phase II NIH SBIR Actuated Medical Inc will complete the development of the Pedi GJ ClearTM device for clearing occlusions and restoring patency in situ to pediatric gastrojejunal feeding tubes GJ tubes eliminating the need to surgically replace clogged tubes Public Health Problem Enteral nutrition is provided for patients that have a functioning lower gas ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Novel liver fibrosis test for early detection and classification

    SBC: IMMUNOTOPE, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): The overall goal of this application is to develop and validate a potential biomarker based assay to determine if it can be used as a noninvasive test to detect the stage of hepatic fibrosis and to predict fibrosis progression in HIV/HCV co-infected patients. Significant fibrosis and cirrhosis are premalignant conditions that greatly increase the risk of the de ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. A Diarylheptanoid Scaffold to Treat Taopathies

    SBC: ALS BIOPHARMA, LLC            Topic: NIA

    DESCRIPTION: We identified the Myrica cerifera (Southern Bayberry) extract using a systematic screen as a potent reducer of the structural protein tau, which accumulates in a group of diseases called the tauopathies . The most prevalent tauopathy is Alzheimer's disease, for which there is renewed interest in the identification of tau- based therapeutic approaches to treat this devastating d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. DC-SIGN Inhibitors for the Treatment of HIV Infection

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some macrophages, and activated B cells. In vivo, DC-SIGN- positive cells were demonstrated in lymph nodes, tonsils, skin, and the subepithelial region of the cervix. DC- SIGN has been shown to bind to a nu ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. New therapeutics for the treatment of Acinetobactor baumannii infections.

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter baumannii. They are responsible for clinically important infections that cause a wide variety of maladies including pneumonia, skin and wound infections, bacteremia and meningitis. In addition, A. baumanni ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Polaris Oncology Survivor Transition (POST) System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The Institute of Medicine (IOM) strongly recommends that all breast cancer patients who are ending active treatment have a survivorship plan. Such a plan should assist patients in moving back to their primary care physician (PCP), provide advice for reducing risk for cancer recurrence or new cancer development, and address the remaining psychosocial challenge ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government